Loading...
XASE
RVP
Market cap20mUSD
Jul 14, Last price  
0.67USD
1D
-1.47%
1Q
-5.31%
Jan 2017
-27.96%
IPO
-93.46%
Name

Retractable Technologies Inc

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-1.73%
Rev. gr., 5y
5.55%
Revenues
0k
-100.00%
24,235,01625,324,51926,289,72027,899,31838,981,83736,219,56232,102,29633,644,50330,785,12734,520,63029,552,20029,826,63634,493,83833,274,70241,797,17981,862,453188,382,45494,818,93843,596,9260
Net income
-12m
L+69.54%
-1,238,323-3,869,484-6,948,104-9,643,580-9,422,3002,400,6941,418,482-4,132,892-6,213,852-2,354,6054,314,318-3,694,907-3,736,038-1,339,9433,148,23424,223,01356,064,2415,078,557-7,011,036-11,886,524
CFO
3m
0.00%
-2,234,899-3,354,031-4,216,671-5,923,242-12,299,7318,730,6725,513,773158,3372,933,569-3,867,822-3,252,157-794,912-2,922,636-1,195,4952,194,63818,997,02932,793,49916,768,1282,766,8482,766,848
Earnings
Aug 12, 2025

Profile

Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. It offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. The company distributes its products through general line and specialty distributors, as well as through international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.
URL
https://retractable.com/
IPO date
May 04, 2001
Employees
190
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
43,597
-54.02%
94,819
-49.67%
Cost of revenue
21,106
55,085
95,672
Unusual Expense (Income)
NOPBT
(21,106)
(11,488)
(853)
NOPBT Margin
Operating Taxes
8,366
(1,905)
84
Tax Rate
NOPAT
(29,472)
(9,583)
(937)
Net income
(11,887)
69.54%
(7,011)
-238.05%
5,079
-90.94%
Dividends
(232)
(232)
(253)
Dividend yield
1.13%
0.70%
0.47%
Proceeds from repurchase of equity
(1,107)
(8,705)
BB yield
3.33%
16.10%
Debt
Debt current
332
304
286
Long-term debt
1,234
1,533
Deferred revenue
(15,078)
Other long-term liabilities
64,773
69,774
75,460
Net debt
(44,231)
(45,751)
(19,927)
Cash flow
Cash from operating activities
2,767
2,767
16,768
CAPEX
(853)
(853)
(16,830)
Cash from investing activities
(10,762)
(10,762)
(31,203)
Cash from financing activities
942
942
4,993
FCF
(23,293)
3,376
(13,701)
Balance
Cash
44,564
47,289
49,379
Long term investments
(27,632)
Excess cash
44,564
45,109
17,006
Stockholders' equity
26,669
39,016
59,150
Invested Capital
125,607
131,583
151,668
ROIC
ROCE
EV
Common stock shares outstanding
29,937
29,937
32,962
Price
0.69
-37.98%
1.11
-32.32%
1.64
-76.33%
Market cap
20,609
-37.98%
33,230
-38.53%
54,061
-77.22%
EV
(23,622)
(12,291)
34,366
EBITDA
(13,536)
(3,961)
3,750
EV/EBITDA
1.75
3.10
9.16
Interest
122
152
171
Interest/NOPBT